The long-term social value of granulocyte colony-stimulating factors.

CONCLUSIONS: Current use of G-CSF prophylaxis would provide $96 billion in SV over the next 10 years. Targeting G-CSF prophylaxis to align with guidelines would more than double SV, highlighting the substantial value of appropriate FN risk assessment and targeted G-CSF prophylaxis. PMID: 31622064 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31622064?dopt=Abstract

Source: The American Journal of Managed Care - September 30, 2019 Category: Health Management Authors: Sexton Ward A, Kabiri M, Yucel A, Silverstein AR, van Eijndhoven E, Bowers C, Bensink M, Goldman D Tags: Am J Manag Care Source Type: research